Filings signal: Despite Covid losses, pharma earnings are promising

Preview

来源: Pharmaceutical Technology

Isaac Hanson

Preview

来源: Pharmaceutical Technology

As Covid-19 product sales dip, other profits remain healthy. Credit: CROCOTHERY / Shutterstock.com.

Each week, Pharmaceutical Technology’s journalists pick out insights from company filings that highlight sentiments in our sector. These filings signals are based on GlobalData’s analysis of earnings statements, call transcripts, investor presentations and sustainability reports. They tell us about key topics on the minds of business leaders and investors, and the themes driving a company’s activities.

This new, thematic filings coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Naltrexone in Low Back Pain GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - (Aceclofenac + Eperisone Sr) in Low Back Pain GlobalData

View allCompanies IntelligenceAstraZeneca PlcTakeda UK LtdRoche GroupRoche S.A.View all

In the last week week, pharmaceutical giants including Takeda, AstraZeneca and Roche released their half-year earnings reports, and the numbers give cause for optimism. Covid-19 profits continue to diminish as demand for vaccines wanes, but sales growth in other product areas remains strong enough to compensate. This refocusing is reflected in the mentions of key industry themes within the filings of the three companies.

Preview

来源: Pharmaceutical Technology

Continuing a trend from Q1, weakening Covid-19 sales are impacting profits, sometimes to the point of exclusion from growth figures. AstraZeneca notes in its H1 report that total revenue was up 4%, but that figure jumps to 16% excluding Covid-19 medications.

Preview

来源: Pharmaceutical Technology

Takeda reported a similar situation, with core operating profit up 2.3% in actual foreign exchange, but down 2% at constant exchange rate, which it attributes in part to Covid-19 product sales. In its Q1 earnings call, CFO Costa Saroukos explained: “This decline reflects product mix due to generic entry and lower Covid-19 vaccineCovid-19 vaccine revenues and also continued investment in R&D and data”.

Preview

来源: Pharmaceutical Technology

Roche Group’s core profit was in fact down 6%, driven predominantly by declining Covid-19 product sales, which fell by CHF 5bn ($5.75bn) in Q2. Despite this, base business sales grew by 8%, indicating long-term sustainability, especially as a large portion of this growth was coming from new medication.

Declining Covid-19 product sales were inevitable as the global vaccination rate continues to increase and governmental funding for prevention tapers off. The exceptional profits created during the pandemic provided big pharma companies with healthy cash reserves, and the return to normal operation appears to be going smoothly.

Another indicator of a healthy market is the mass investment in artificial intelligence (AI) that many of these companies are undertaking. Of particular interest is Roche’s in-house language model that functions similarly to ChatGPT announced in early 2022.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。